Sangamo Therapeutics France S.A.S., a biotechnology company, develops cellular immunotherapies based on regulatory T cells Tregs for inflammation, autoimmunity, and transplantation. Its cellular therapy products are composed of Tregs with a chimeric antigen receptor CAR. The company’s product candidates include TX200, a CAR-Treg-based cellular immunotherapy for the prevention of graft rejection in the context of solid organ transplantation. It is also involved in the development of CAR-Treg-based cellular immunotherapies for bullous pemphigoid, a rare potentially fatal autoimmune disease, as well as for the treatment of multiple sclerosis; and Ovasave for refractory Crohn's disease. The company has strategic research and development collaboration agreements with the Lübeck Institute of Experimental Dermatology, University of British Columbia, and Center for Research in Transplantation and Immunology. Sangamo Therapeutics France S.A.S. is headquartered in Valbonne, France. As of October 1, 2018, Sangamo Therapeutics France S.A.S. operates as a subsidiary of Sangamo Therapeutics, Inc.